Hengrui, Kailera’s GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsnews2026-07-07T15:25:44+00:00July 7th, 2026|Endpoints News|
After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pactnews2026-07-02T17:06:45+00:00July 2nd, 2026|Endpoints News|
WuXi AppTec seeks injunction over China military listnews2026-07-01T17:52:54+00:00July 1st, 2026|Endpoints News|
House China panel probes Bristol Myers, Pfizer on use of trial sitesnews2026-06-30T10:00:31+00:00June 30th, 2026|Endpoints News|
Post-Hoc: China deals are pharma’s new tax inversions news2026-06-29T13:00:31+00:00June 29th, 2026|Endpoints News|
Akeso pushes back on ASCO questioning of lung cancer drugnews2026-06-26T15:33:07+00:00June 26th, 2026|Endpoints News|
RTW’s Rod Wong on how China has (and hasn’t) changed his firm’s investmentsnews2026-06-25T17:11:13+00:00June 25th, 2026|Endpoints News|
Lilly offers up to $1.9B in new drug discovery deal with Abbiskonews2026-06-24T10:14:04+00:00June 24th, 2026|Endpoints News|
BIO board met with US officials on China, CEO saysnews2026-06-23T18:18:50+00:00June 23rd, 2026|Endpoints News|
Post-Hoc Live: Are the China hawks winning?news2026-06-22T12:46:32+00:00June 22nd, 2026|Endpoints News|
